Thermo Fisher scientific and bioMérieux renew partnership for improved detection of sepsis
This agreement extends a long-standing relationship between the companies for biomarker testing using Thermo Fisher’s PCT product on bioMérieux’s VIDAS® and mini VIDAS® immunoassay platforms, and now also includes the new-generation VIDAS® products.
The PCT biomarker test is the gold standard for the early detection of sepsis in critically ill patients. In Europe, the test helps doctors make an early determination whether an infection is bacterial or viral and provides information on the severity of a patient’s condition for appropriate treatment. In the United States, the PCT test is marketed for use on the first day of ICU admission, and, combined with other laboratory tests and clinical assessment, aids in risk assessment of critically ill patients for progression to severe sepsis and septic shock. Broader availability of PCT testing for diagnosing sepsis will lead to improved hospital management and patient care.